Retinoblastoma Market - 2024-2031

Report Overview

The Global Retinoblastoma Market reached US$ 970.15 million in 2023 and is expected to reach US$ 1440.28 million by 2031, growing at a CAGR of 5.2% during the forecast period 2024-2031.

Retinoblastoma is a very rare childhood cancer that forms in the tissues of the retina. It can occur in one or both eyes. Most cases of retinoblastoma are not inherited, but some are, and children with a family history of the disease should have their eyes checked beginning at an early age. Retinoblastoma is generally diagnosed by various methods like examination of dilated pupils, ophthalmoscopy, fluorescein angiography, electroretinography, RB1 gene test, ultrasound examination of the eye, magnetic resonance imaging of the eye, and biopsy in some cases.

The outlook for retinoblastoma has improved significantly as therapy and early detection techniques have advanced. However, the condition can have long-term repercussions on a child's vision and overall health, necessitating regular follow-up care to manage long-term outcomes and handle any potential issues.

Market Dynamics: Drivers

Increasing demand for new drugs and treatments drives the market

The increasing demand for new drugs and treatment drives propels the market growth. In recent years, the demand for innovative drugs and treatments has increased for enhanced patient outcomes due to the increasing prevalence of retinoblastoma in children. Personalized medicine involves tailoring treatments to individual patients based on their unique genetic profile and disease characteristics gained prominence in oncology including retinoblastoma. The demand for innovative drugs in retinoblastoma is continuously increasing to provide more precise and effective therapies, potentially leading to better treatment outcomes.

For instance, in February 2023, Alephoson Biopharmaceuticals Ltd. disclosed peptide-drug conjugates comprising a cell-penetrating peptide covalently linked to melphalan that is reported to be useful for the treatment of retinoblastoma. Moreover, many clinical trials and research activities are going on rapidly, leading to many innovative inventions for better treatment. The innovative treatment options also include technological advancements, these advancements help in a better understanding of the disease and its mechanisms resulting in better and enhanced patient outcomes. Hence, many clinical trials and research activities are being performed for innovative treatment options.

Restraints

Factors such as high costs associated with the treatment is expected to hamper the market. The targeted therapies are showing promising results in clinical trials, but they can be costly to develop and manufacture. The research and development costs for these innovative treatments, coupled with the expenses of conducting clinical trials, may lead to higher prices for these drugs, impacting their affordability for patients seeking retinoblastoma treatment.

Market Segment Analysis

The retinoblastoma market is segmented based on disease type, application, end-user, and region.

The segment inheritance retinoblastoma accounted for approximately 48.3% of the retinoblastoma market share

The inheritance segment is expected to hold the largest market share over the forecast period. The non-hereditary retinoblastoma is also known as sporadic retinoblastoma. About 60% of children with retinoblastoma have non-hereditary retinoblastoma. Commonly, children are born with 2 normal copies of the RB1 gene. A mutation of both copies of the RB1 gene in a retinoblast causes a retinoblastoma tumor to form in the eyes of the children. Children with non-hereditary retinoblastoma only develop a tumor in one eye known as unilateral retinoblastoma. They will not usually pass the RB1 mutation on to their future children.

Market Geographical Analysis

North America accounted for approximately 43.5% of the retinoblastoma market share

North America region is expected to hold the largest market share over the forecast period. The technological advancements in this region, help to propel the market. Though retinoblastoma is a rare disease, there is a high prevalence of this type of cancer in North America. The availability of comprehensive cancer treatments and advanced diagnostic capabilities allows for better disease monitoring, management, and treatment.

According to the National Cancer Institute, there are 200 to 350 children in the United States who are estimated to be diagnosed annually with the disease. North America, especially the United States is home to several major pharmaceutical companies, medical device manufacturers, and research institutions that are actively involved in the development and commercialization of retinoblastoma drugs and treatments. The region's established pharmaceutical and healthcare sectors attract significant investments and foster innovations in retinoblastoma treatments.

Market Segmentation

By Disease Type

Laterality

Unilateral Retinoblastoma

Bilateral Retinoblastoma

Trilateral Retinoblastoma

Inheritance

Hereditary Retinoblastoma

Non-Hereditary Retinoblastoma

By Treatment

Surgery

Radiation Therapy

Cryotherapy

Laser Therapy

Chemotherapy

Cyclophosphamide

Carboplatin

Vincristine

Others

By End-User

Hospitals

Ophthalmic Clinics

Cancer Research Centers

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the retinoblastoma market include Pfizer Inc., Bristol Myers Squibb Company, Teva Pharmaceutical Pvt Ltd., Merck and Co., Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson, Baxter International, Inc., AbbVie Inc., and Hikma Pharmaceuticals Plc among others.

Key Developments

In August 2024, Theriva Biologics Inc. received an FDA-granted rare pediatric drug designation for VCN-01 as a treatment for pediatric patients with retinoblastoma.

In July 2023, the FDA approved a new drug application (NDA) for 200-mg/mL vials of cyclophosphamide injection for use in combination therapy for the treatment of various cancers including retinoblastoma. The approval is expected to demonstrate the safety and efficacy of the product and help the company broaden the available treatment options.

Why Purchase the Report?

To visualize the retinoblastoma market segmentation based on disease type, application, end-user, and region, as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of retinoblastoma market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping is available in Excel consisting of key products of all the major players.

The retinoblastoma market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies